Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

The old pharmaceutical oleoresin labdanum of Cistus creticus L. exerts pronounced in vitro anti-dengue virus activity.

Kuchta K, Tung NH, Ota T, Raekiansyah M, Grötzinger K, Rausch H, Shoyama Y, Rauwald HW, Morita K.

J Ethnopharmacol. 2019 Oct 26:112316. doi: 10.1016/j.jep.2019.112316. [Epub ahead of print]

PMID:
31669444
2.

Labdanum and Labdanes of Cistus creticus and C. ladanifer: Anti-Borrelia activity and its phytochemical profiling.

Rauwald HW, Liebold T, Grötzinger K, Lehmann J, Kuchta K.

Phytomedicine. 2019 Jul;60:152977. doi: 10.1016/j.phymed.2019.152977. Epub 2019 May 31.

PMID:
31474477
3.

Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.

Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB.

Br J Haematol. 2019 Apr;185(1):102-106. doi: 10.1111/bjh.15732. Epub 2018 Dec 27.

PMID:
30592022
4.

Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.

Khelif A, Saleh MN, Salama A, Portella MDSO, Duh MS, Ivanova J, Grotzinger K, Roy AN, Bussel JB.

Am J Hematol. 2019 Feb;94(2):200-208. doi: 10.1002/ajh.25348. Epub 2018 Nov 29.

5.

Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales.

Allen R, Bryden P, Grotzinger KM, Stapelkamp C, Woods B.

Value Health. 2016 Jul-Aug;19(5):614-22. doi: 10.1016/j.jval.2016.03.1856. Epub 2016 May 11.

6.

Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.

Grotzinger KM, Younossi ZM, Giannini EG, Chen PJ, Rendas-Baum R, Theodore D.

Health Qual Life Outcomes. 2016 Mar 22;14:49. doi: 10.1186/s12955-016-0447-1.

7.

Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia.

Irving WL, Grotzinger K, Theodore D, Demuth D, Rizzetto M, Roughley A, Forssen U.

J Viral Hepat. 2015 May;22(5):511. doi: 10.1111/jvh.12357. No abstract available.

PMID:
25847467
8.

Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.

Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M.

Int J Hematol. 2015 Mar;101(3):255-63. doi: 10.1007/s12185-014-1731-7. Epub 2015 Jan 14.

PMID:
25586660
9.

Severity of liver disease among chronic hepatitis C patients: an observational study of 4594 patients in five European countries.

Marcellin P, Grotzinger K, Theodore D, Demuth D, Manns M, Bañares Cañizares R, Pike J, Forssen UM.

J Gastroenterol Hepatol. 2015 Feb;30(2):364-71. doi: 10.1111/jgh.12698.

PMID:
25088088
10.

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.

Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, Miller WH Jr, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann S, Hauschild A.

Ann Oncol. 2014 Jul;25(7):1428-36. doi: 10.1093/annonc/mdu154. Epub 2014 Apr 25.

PMID:
24769640
11.

Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries.

Rizzetto M, Grotzinger K, Theodore D, Demuth D, Irving WL, Manns M, Roughley A, Forssen UM.

J Viral Hepat. 2014 Oct;21(10):e129-34. doi: 10.1111/jvh.12256. Epub 2014 Apr 3.

PMID:
24698004
12.

Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.

Hermos JA, Quach L, Gagnon DR, Weber HC, Altincatal A, Cho K, Lawler EV, Grotzinger KM.

Pharmacoepidemiol Drug Saf. 2014 May;23(5):480-8. doi: 10.1002/pds.3585. Epub 2014 Feb 20.

PMID:
24677630
13.

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C.

Ann Oncol. 2014 Mar;25(3):700-6. doi: 10.1093/annonc/mdt580. Epub 2014 Feb 6.

14.

A comment on Boyers et al.: "eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal".

Allen R, Brainsky A, Grotzinger K, Roccia T.

Pharmacoeconomics. 2013 Jan;31(1):87-9. doi: 10.1007/s40273-012-0003-8. No abstract available.

15.

Thrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease.

Hermos JA, Altincatal A, Weber HC, Grotzinger K, Smoot KJ, Cho K, Gagnon DR, Lawler EV.

Dig Dis Sci. 2013 Feb;58(2):562-73. doi: 10.1007/s10620-012-2404-0. Epub 2012 Sep 26.

PMID:
23010745
16.

Allium ursinum L.: bioassay-guided isolation and identification of a galactolipid and a phytosterol exerting antiaggregatory effects.

Sabha D, Hiyasat B, Grötzinger K, Hennig L, Schlegel F, Mohr FW, Rauwald HW, Dhein S.

Pharmacology. 2012;89(5-6):260-9. doi: 10.1159/000337380.

PMID:
22507958
17.

Patient-reported treatment burden of chronic immune thrombocytopenia therapies.

Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL.

BMC Blood Disord. 2012 Mar 22;12:2. doi: 10.1186/1471-2326-12-2.

18.

Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.

Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM.

Curr Med Res Opin. 2012 Jan;28(1):79-87. doi: 10.1185/03007995.2011.644849. Epub 2011 Dec 20.

PMID:
22117897
19.

Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients.

Poordad F, Theodore D, Sullivan J, Grotzinger K.

J Med Econ. 2012;15(1):112-24. doi: 10.3111/13696998.2011.632463. Epub 2011 Nov 4.

PMID:
21995622
20.

Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.

Signorovitch J, Brainsky A, Grotzinger KM.

Qual Life Res. 2011 Dec;20(10):1737-44. doi: 10.1007/s11136-011-9912-9. Epub 2011 May 1.

PMID:
21533818
21.

Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.

Poordad F, Theodore D, Sullivan J, Grotzinger K.

J Med Econ. 2011;14(2):194-206. doi: 10.3111/13696998.2011.562266. Epub 2011 Feb 25.

PMID:
21348807
22.

Growth inhibiting activity of volatile oil from Cistus creticus L. against Borrelia burgdorferi s.s. in vitro.

Hutschenreuther A, Birkemeyer C, Grötzinger K, Straubinger RK, Rauwald HW.

Pharmazie. 2010 Apr;65(4):290-5.

PMID:
20432627
23.

Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies.

Hauber AB, Johnson FR, Grotzinger KM, Ozdemir S.

Ann Pharmacother. 2010 Mar;44(3):479-88. doi: 10.1345/aph.1M567. Epub 2010 Feb 2.

PMID:
20124463
24.

Treatment practices in adults with chronic immune thrombocytopenia - a European perspective.

Rodeghiero F, Besalduch J, Michel M, Provan D, Grotzinger K, Thompson G.

Eur J Haematol. 2010 Feb 1;84(2):160-8. doi: 10.1111/j.1600-0609.2009.01361.x. Epub 2009 Oct 21.

PMID:
19845743
25.

Analysis of the impact and burden of illness of adult chronic ITP in the US.

Saleh MN, Fisher M, Grotzinger KM.

Curr Med Res Opin. 2009 Dec;25(12):2961-9. doi: 10.1185/03007990903362388.

PMID:
19835465
26.

A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries.

Two R, Verjee-Lorenz A, Clayson D, Dalal M, Grotzinger K, Younossi ZM.

Value Health. 2010 Jan-Feb;13(1):128-31. doi: 10.1111/j.1524-4733.2009.00585.x. Epub 2009 Aug 20.

27.

Antiplatelet activity of Allium ursinum and Allium sativum.

Hiyasat B, Sabha D, Grotzinger K, Kempfert J, Rauwald JW, Mohr FW, Dhein S.

Pharmacology. 2009;83(4):197-204. doi: 10.1159/000196811. Epub 2009 Jan 28.

PMID:
19174616
28.
29.

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

Ramlau R, Gervais R, Krzakowski M, von Pawel J, Kaukel E, Abratt RP, Dharan B, Grotzinger KM, Ross G, Dane G, Shepherd FA.

J Clin Oncol. 2006 Jun 20;24(18):2800-7. Epub 2006 May 8.

PMID:
16682727
30.

Assessment and control of nonresponse bias in a survey of medicine use by the elderly.

Grotzinger KM, Stuart BC, Ahern F.

Med Care. 1994 Oct;32(10):989-1003.

PMID:
7934275
31.

Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate.

Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC.

Cancer Chemother Pharmacol. 1988;22(2):147-52.

PMID:
3409446
32.

Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF.

Cancer Res. 1987 Jan 15;47(2):414-8.

33.

Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines.

Louie KG, Hamilton TC, Winker MA, Behrens BC, Tsuruo T, Klecker RW Jr, McKoy WM, Grotzinger KR, Myers CE, Young RC, et al.

Biochem Pharmacol. 1986 Feb 1;35(3):467-72.

PMID:
3947382
34.
35.

Activity of tricyclic nucleoside 5'-phosphate in model systems of human ovarian cancer.

Behrens BC, Hamilton TC, Louie KG, Grotzinger KR, McKoy WM, Tsuruo T, Young RC, Ozols RF.

Invest New Drugs. 1986;4(4):295-304.

PMID:
3583641
36.

Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma.

Louie KG, Hamilton TC, Behrens BC, Grotzinger KR, McKoy WM, Myers CE, Young RC, Ozols RF.

Cancer Chemother Pharmacol. 1986;18(2):153-6.

PMID:
3466726
37.

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF.

Biochem Pharmacol. 1985 Jul 15;34(14):2583-6. No abstract available.

PMID:
4040369
38.

Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.

Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, Ozols RF.

Cancer Res. 1985 May;45(5):2110-5.

39.

Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.

Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozols RF.

Cancer Res. 1984 Nov;44(11):5286-90.

40.

Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF.

Cancer Res. 1983 Nov;43(11):5379-89.

41.

Effects of amphotericin B on adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and in L1210 leukemia.

Ozols RF, Hogan WM, Grotzinger KR, McCoy W, Young RC.

Cancer Res. 1983 Mar;43(3):959-64. No abstract available.

42.

Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites.

Ozols RF, Willson JK, Weltz MD, Grotzinger KR, Myers CE, Young RC.

Cancer Res. 1980 Nov;40(11):4109-12.

43.

Cloning of human ovarian cancer cells in soft agar from malignant and peritoneal washings.

Ozols RF, Willson JK, Grotzinger KR, Young RC.

Cancer Res. 1980 Aug;40(8 Pt 1):2743-7. No abstract available.

44.

Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.

Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC.

Cancer Res. 1979 Aug;39(8):3209-14. No abstract available.

45.

Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer.

Ozols RF, Grotzinger KR, Fisher RI, Myers CE, Young RC.

Cancer Res. 1979 Aug;39(8):3202-8. No abstract available.

46.

Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.

Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Fisher RI, Young RC.

Cancer Treat Rep. 1979 Feb;63(2):269-73.

PMID:
445504
47.

Alterations in [3H]thymidine incorporation into DNA and [3H]uridine incorporation into RNA induced by 5-azacytidine in vivo.

McGuire W, Grotzinger K, Young R.

Biochem Pharmacol. 1978 Mar 1;27(5):745-50. No abstract available.

PMID:
77668
48.

Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.

Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC.

Science. 1977 Jul 8;197(4299):165-7.

PMID:
877547

Supplemental Content

Loading ...
Support Center